home / stock / xomap / xomap news

XOMAP News and Press, XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock From 04/25/24

Stock Information
Company Name: XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
Stock Symbol: XOMAP
Market: NASDAQ
Website: xoma.com
Menu
XOMAP XOMAP Quote XOMAP Short XOMAP News XOMAP Articles XOMAP Message Board
Get XOMAP Alerts

News, Short Squeeze, Breakout and More Instantly...
XOMAP - XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE N...
XOMAP - XOMA Corporation Announces Closing of Tender Offer

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced th...

XOMAP - XOMA Corp (XOMAP) announced stock dividend $0.53906 on Ex-Date April 02, 2024

2024-04-01 09:00:14 ET XOMA Corp (XOMAP) declaring a stock dividend of $0.53906 per share on Ex-Date : April 02, 2024. Shareholders on record as of April 03, 2024 are eligible for the dividend. The payment date is scheduled for April 15, 2024, and the declaration was officially made...

XOMAP - XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (“XOMA” or the “Company”; Nasdaq: XOMA) entered into a merger agreement to acquire Kinnate Biopharma Inc. (“Kinnate”; Nasdaq: KNTE) for (...
XOMAP - XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related to our growing royalty base and the achievement of certain development milestones ...

XOMAP - XOMA to Present at Upcoming Investor Conferences in March

EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences: The 44 th Annual TD Cowen Health Care Conference taki...

XOMAP - XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0...
XOMAP - Long Term Trading Analysis for (XOMAP)

2024-02-15 22:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

XOMAP - (XOMAP) Technical Pivots with Risk Controls

2024-02-05 20:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

XOMAP - (XOMAP) Trading Report

2024-01-23 10:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Previous 10 Next 10